(Q34206981)

31 July 2017

1 reference

title

The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis (English)

1 reference

31 July 2017

0 references

1 reference

Lufkin EG

1

1 reference

31 July 2017

Wong M

series ordinal

2

1 reference

31 July 2017

Deal C

series ordinal

3

1 reference

31 July 2017

publication date

1 February 2001

1 reference

Rheumatic Diseases Clinics of North America

31 July 2017

published in

1 reference

31 July 2017

volume

27

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

163-85, vii

1 reference

Management of corticosteroid-induced osteoporosis

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Tamoxifen and the endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Hormone replacement therapy, heart disease, and other considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

A review of clinical trials of therapies for osteoporosis using fracture as an end point

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Effects of raloxifene hydrochloride on the endometrium of postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Vitamin D3 and calcium to prevent hip fractures in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Hip fractures in the elderly: a world-wide projection

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Calcium for prevention of osteoporotic fractures in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Epidemiology of hip fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Adverse events reported by postmenopausal women in controlled trials with raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

How should the risk of fracture in postmenopausal women be assessed?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

The long-term skeletal effects of EHDP in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Do Markers of Bone Resorption Add to Bone Mineral Density and Ultrasonographic Heel Measurement for the Prediction of Hip Fracture in Elderly Women? The EPIDOS Prospective Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Dietary calcium and risk of hip fracture: 14-year prospective population study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

The burden of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Effect of calcitonin on vertebral and other fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Evaluation of the risk of hip fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Treatment of postmenopausal osteoporosis with transdermal estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Bone status and fracture rates in two regions of Yugoslavia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Epidemiology of spinal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

A "Gompertzian" view of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Determinants of bone loss from the femoral neck in women of different ages

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Long-term fracture prediction by bone mineral assessed at different skeletal sites

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Relationship of bone turnover to bone density and fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Secondary osteoporosis and the risk of vertebral deformities in women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Selective estrogen receptor modulators: a look ahead

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

The association of radiographically detected vertebral fractures with back pain and function: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Bone mineral density predicts non-spine fractures in very elderly women. Study of Osteoporotic Fractures Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Tamoxifen in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Progestogen intolerance and compliance with hormone replacement therapy in menopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Involutional osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

The worldwide problem of osteoporosis: insights afforded by epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Pre-existing fractures and bone mass predict vertebral fracture incidence in women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

Events per person year--a dubious concept

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970192-7

7 January 2021

10.1016/S0889-857X(05)70192-7

Identifiers

DOI

1 reference

31 July 2017

1 reference